Astrocytoma, IDH-Mutant — Trials

Astrocytoma, IDH-Mutant — Trials · CancerIndex

Clinical trials

Registered studies

25 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

clinicaltrialsPublishedShowing 1–25 of 25 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	recruiting	Phase 1 / Phase 2	134	Neonc Technologies, Inc.INDUSTRY	1	Sep 24, 2026	clinicaltrials
NCT03528642	Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	active not recruiting	Phase 1	23	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT07703436	Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease	not yet recruiting	Phase 2	40	Nuvation Bio Inc.INDUSTRY	1	Sep 22, 2026	clinicaltrials
NCT07831369

Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials